RXi Pharmaceuticals Corp (RXII)

0.52
NASDAQ : Health Care
Prev Close 0.50
Day Low/High 0.49 / 0.52
52 Wk Low/High 0.48 / 2.93
Avg Volume 249.20K
Exchange NASDAQ
Shares Outstanding 23.70M
Market Cap 11.85M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

RXi Pharmaceuticals Announces The Departure Of Dr. Alexey Eliseev As Chief Business Officer

RXi Pharmaceuticals Announces The Departure Of Dr. Alexey Eliseev As Chief Business Officer

Dr. James Cardia, RXi's Director of Business Development and Intellectual Property, will take over the management of the Company's ongoing business development and partnering initiatives

BioAxone BioSciences Awarded NINDS SBIR Funding For The Development Of Self-Delivering RNAi (sd-rxRNA®) For The Treatment Of Spinal Cord Injury

BioAxone BioSciences Awarded NINDS SBIR Funding For The Development Of Self-Delivering RNAi (sd-rxRNA®) For The Treatment Of Spinal Cord Injury

RXi Pharmaceuticals is a collaborator on this grant and will receive a portion of the allotted funding for the development of sd-rxRNA therapeutic compounds targeting PTEN

RXi Pharmaceuticals Corporation Selected To Present At The 8th Annual Investing For Cures Forum

RXi Pharmaceuticals Corporation Selected To Present At The 8th Annual Investing For Cures Forum

The forum brings together leading family offices, high net worth private investors, pharma and foundations to explore the latest innovations transforming healthcare.

RXi Pharmaceuticals Announces Completion Of Enrollment Of Phase 1/2 Clinical Trial With RXI-109 For Retinal Scarring

Study RXI-109-1501 is evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases

RXi Pharmaceuticals Announces The Initiation Of Its Consumer Testing Program With RXI-231

RXI-231 is in development as a cosmetic ingredient that may improve the appearance of uneven skin tone and pigmentation

RXi Pharmaceuticals Corporation Selected To Present At The Cavendish Global Health Impact Forum

Forum brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

RXi Pharmaceuticals Granted Patent In Japan For Lead Clinical Candidate RXI-109

RXI-109 is a self-delivering RNAi compound (sd-rxRNA) in development to reduce dermal and ocular fibrosis

RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum

Focusing on Advances in Immuno-Oncology

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Stocks with insider trader activity include RXII, MA and SWN